Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Net Cash Flow: 2013-2025

Historic Net Cash Flow for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $11.8 million.

  • Fortress Biotech's Net Cash Flow rose 168.20% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.5 million, marking a year-over-year increase of 291.79%. This contributed to the annual value of -$24.6 million for FY2024, which is 74.84% up from last year.
  • Per Fortress Biotech's latest filing, its Net Cash Flow stood at $11.8 million for Q3 2025, which was up 169.79% from -$17.0 million recorded in Q2 2025.
  • Fortress Biotech's Net Cash Flow's 5-year high stood at $56.5 million during Q1 2021, with a 5-year trough of -$65.7 million in Q2 2023.
  • Moreover, its 3-year median value for Net Cash Flow was -$7.6 million (2024), whereas its average is -$8.5 million.
  • The largest annual percentage gain for Fortress Biotech's Net Cash Flow in the last 5 years was 6,279.89% (2021), contrasted with its biggest fall of 210.35% (2021).
  • Over the past 5 years, Fortress Biotech's Net Cash Flow (Quarterly) stood at $53.6 million in 2021, then crashed by 155.26% to -$29.6 million in 2022, then soared by 129.10% to $8.6 million in 2023, then slumped by 124.37% to -$2.1 million in 2024, then skyrocketed by 168.20% to $11.8 million in 2025.
  • Its Net Cash Flow stands at $11.8 million for Q3 2025, versus -$17.0 million for Q2 2025 and $33.7 million for Q1 2025.